ScreenerHero

COYA Coya Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · coyatherapeutics.com
4.990USD+1.63%Mkt Cap: 117.05M $P/E: —

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on thera…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap117.05M USD
Enterprise Value72.00M USD
Revenue (TTM)8.02M USD
Gross Profit-8.97M USD
Net Income (TTM)-21.23M USD
Revenue/Share0.40 USD
Last Price4.990 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.65
PEG—
EV/EBITDA-3.46
EV/Revenue8.98
P/S14.60
P/B2.70
EPS (TTM)-1.09
EPS (Forward)-1.88
52W Range
3.71032% of range7.750
52W High7.750 USD
52W Low3.710 USD
Profitability
Gross Margin-111.80%
Oper. Margin-2890.45%
EBITDA Margin-259.76%
Profit Margin-267.14%
ROE-49.33%
ROA-42.49%
Growth
Revenue Growth49.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.74M USD
CapEx (TTM)—
FCF Margin-136.48%
FCF Yield-9.35%
Net Debt-43.18M USD
Net Debt/EBITDA2.07
Balance Sheet
Debt/Equity—
Current Ratio13.40
Quick Ratio12.29
Book Value/Sh1.84 USD
Cash/Share1.84 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.21 USD
Upside (mean)+204.9%
Target Range12.00 USD – 18.00 USD
12.00+204.9% to mean18.00
# Analysts7
Ownership
Shares Out.23.46M
Float17.54M
Insiders14.69%
Institutions33.26%
Short Interest
Short Ratio11.3d
Short % Float5.11%
Short % Out.5.06%
Shares Short1.19M
Short (prev mo.)1.06M
Technical
SMA 504.749 (+5.1%)
SMA 2004.726 (+5.6%)
Beta0.58
S&P 52W Chg15.84%
Avg Vol (30d)126.70K
Avg Vol (10d)101.30K
Technical Indicators
RSI (14)54.8
MACD0.0537
MACD Signal0.0632
MACD Hist.-0.0096
BB Upper5.326 USD
BB Middle4.870 USD
BB Lower4.414 USD
BB Width18.74%
ATR (14)0.2546 USD
Vol Ratio (20d)1.03x